0: Included participants were aged 18 years at the time of informed consent.
1: Participants had to present with active DLE or SCLE skin disease (with or without systemic manifestations of SLE).
2: 42 43 Concomitant antimalarial or systemic immunosuppressive therapies were allowed if doses were stable for 28 days before the day 1 visit.
3: Prednisone or equivalent maximum dosage was 15 mg/day.
4: High-potency topical steroids and/or other topical agents had to be stopped 7 days before the day 1 visit.
5: HVs had to be in good overall health as determined by the investigator.
6: For further details, see inclusion and exclusion criteria in online supplementary materials.
